Cortexyme (NASDAQ:CRTX) & Gamida Cell (NASDAQ:GMDA) Critical Comparison

Share on StockTwits

Cortexyme (NASDAQ:CRTX) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Profitability

This table compares Cortexyme and Gamida Cell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cortexyme N/A -58.22% -26.73%
Gamida Cell N/A -215.37% -89.08%

Analyst Ratings

This is a breakdown of current recommendations for Cortexyme and Gamida Cell, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cortexyme 1 1 1 0 2.00
Gamida Cell 0 0 3 0 3.00

Cortexyme presently has a consensus target price of $34.25, indicating a potential downside of 52.77%. Gamida Cell has a consensus target price of $17.67, indicating a potential upside of 275.09%. Given Gamida Cell’s stronger consensus rating and higher possible upside, analysts clearly believe Gamida Cell is more favorable than Cortexyme.

Institutional and Insider Ownership

20.6% of Cortexyme shares are owned by institutional investors. Comparatively, 23.9% of Gamida Cell shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cortexyme and Gamida Cell’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cortexyme N/A N/A -$12.48 million N/A N/A
Gamida Cell N/A N/A -$52.93 million ($10.53) -0.45

Summary

Gamida Cell beats Cortexyme on 4 of the 7 factors compared between the two stocks.

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.